Phase 2 N=27 Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
Alcohol-Related Disorders · Alcohol Drinking · Alcoholism
Primary: Weekly Change in Drinking — -11.4; -22.2; -39.6; -29.3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=82 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Respiratory Syncytial Virus
Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) — 93.64; 62.53; 73.75; 78.34 days x Score
Phase 4 N=319 Increasing Naloxone Access for Persons Who Use Opioids
Naloxone
Primary: The Number of Participants That Completed the Training in 6 Months — 55; 56; 10; 9 Participants
N/A N=14 PRP vs PRP Plus IGF for Patellar Tendinosis
Tendinopathy · Patellar Ligament · Platelet-Rich Plasma
Primary: Victorian Institute of Sport Assessment-patellar Tendon (VISA-P) — 66.4; 78.2 units on a scale — p=0.433
Phase 4 N=60 Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control
Cesarean Section Complications · Pain · Opioid Use
Primary: Total Opioid Usage in Oral Morphine Equivalents — 8; 2 morphine milligram equivalents
Phase 1 N=73 Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=98 An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) — 74.6; 46.2 Percentage of Participants
N/A N=267 Testing Legally Feasible Options: Study 1
Tobacco Use
Primary: Proportion of Participants Susceptible to Smoking Cigarettes After Shopping in the StoreLab (Non-flavored) — .18; .23; .33 proportion of participants
Early Phase 1 N=35 taVNS Paired With Bottle Feeding in Infants Failing Oral Feeds
Poor Feeding · Infant Development · Vagus Nerve Stimulation
Primary: Number of Infants Who Took All Feeds by Mouth (Responders) — 8; 11 Participants
Phase 3 N=10 Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
CD55-deficient Protein-losing Enteropathy · CHAPLE
Primary: Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24 — 100…
Phase 1 N=8 Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)
HIV/AIDS · HIV Prevention
Primary: Tenofovir Diphosphate (TFV-DP) Concentration — 2441; 3472; 406 femtomole/million cells
Phase 2 N=42 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Breast Cancer
Primary: Phase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both — 100; 65; 100 percentage of participants
Phase 3 N=1,403 Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
Respiratory Syncytial Virus
Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or Placebo — 10.1; 6.5; 7.6; 11.5 Percentage of participants
Phase 2 N=18 Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 50.0; 10.0 Percentage of participants
Phase 3 N=500 Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
Colonoscopy
Primary: Proportion of Subjects With Successful Bowel Preparation — 212; 211 Participants — p=<0.001